Duration of immunity in dogs after vaccination or naturally acquired infection

Veterinary Record

Volumn 149, Issue 17, 2001, Pages 509-515

  Coyne, M J ^a   Burr, J H H ^b   Yule, T D ^c   Harding, M J ^c   Tresnan, D B ^c   McGavin, D ^c  

^a PFIZER INC   (United States)

^b ZOETIS   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ARTICLE; BORDETELLA BRONCHISEPTICA; BORRELIA BURGDORFERI; CANINE DISTEMPER MORBILLIVIRUS; CELLULAR IMMUNITY; CONTROLLED STUDY; CORONAVIRUS; DOG; DRUG SCREENING; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOASSAY; LEPTOSPIRA INTERROGANS; METHODOLOGY; NONHUMAN; PARAINFLUENZA VIRUS; PARVOVIRUS; PASSIVE IMMUNIZATION; RABIES; STANDARDIZATION; VACCINATION;

BORDETELLA BRONCHISEPTICA; BORRELIA; BORRELIA BURGDORFERI; CANINE DISTEMPER VIRUS; CANIS FAMILIARIS; CORONAVIRUS; LEPTOSPIRA INTERROGANS; PARVOVIRUS;

EID: 0035960308     PISSN: 00424900     EISSN: None     Source Type: Journal    
DOI: 10.1136/vr.149.17.509     Document Type: Article

References (71)

1. Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel of Feline Vaccines
2. Gleichzeitige immunisierung von hunden gegen parvovirose, staupe, tollwut, H.c.c. und leptospirose
3. Infectious Diseases of Humans: Dynamics and Control
4. Pathogenicity of low-virulence strains of two canine adenovirus types
5. Canine distemper virus
6. Isolation and immunisation studies of a canine parvo-like virus from dogs with haemorhagic enteritis
7. Vaccinations associées du chien. Durée d'immunité Carré-Rubarth
8. Zur prüfung der immunitätsdauer von tollwut-kombinationsvaccinen am hund
9. Bordetella bronchiseptica in dogs: Bacteriological studies, pathogenesis, immune response and antibiotic treatment
10. Urban rabies
11. Immunogenicity and humoral and cell-mediated immune responses to leptospiral whole cell, outer envelope, and protoplasmic cylinder vaccines in hamsters and dogs
12. Intranasal vaccination of dogs with live avirulent Bordetella bronchiseptica: Correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis
13. Modified-live virus rabies vaccine produced from Flury high egg passage virus grown on an established canine kidney cell line: Three-year duration of immunity study in dogs
14. A modified live canine parvovirus strain with novel plaque characteristics. I. Viral attenuation and dog response
15. A modified live canine parvovirus vaccine. II. Immune response
16. Duration of immunity in dogs inoculated with an inactivated feline parvovirus vaccine
17. Control of canine distemper
18. Canine parainfluenza-Bordetella bronchiseptica vaccine: Immunogenicity
19. Serological results of a dog vaccination campaign against rabies in Peru
20. Immunogenicity and efficacy study of a commercial Borrelia burgdorferi bacterin
21. Rethinking canine vaccinations
22. Immunization coverage required to prevent outbreaks of dog rabies
23. Comparaison de l'efficacité des differents vaccins du chien, utilises sous forme monovalente ou associée, par évaluation des responses serologiques et après epreuves virulentes 12, 22 pet 26 mois après vaccination
24. Diphtheria
25. Vaccine-associated immune-mediated hemolytic anemia in the dog
26. Outbreaks of canine distemper in vaccinated dogs in Finland
27. Efficacy of an inactivated vaccine against clinical disease caused by canine coronavirus
28. Vaccination antirabique de chien et du chat: Taux d'anticorps et résistance a l'épreuve virulente deux ans après l'injection de rappel d'un vaccin additionně d'adjuvant
29. Interpretation of serological surveillance data for measles using mathematical models: Implications for vaccine strategy
30. The immune response of dogs to distemper virus
31. Control of bordetellosis in the dog
32. Duration of vaccination immunity and the influence on subsequent prophylaxis
33. Humoral immune response of dogs after vaccination against leptospirosis measured by an IgM and IgG specific ELISA
34. Postvaccinal sarcomas in the cat: Epidemiology and electron probe microanalytical identification of aluminum
35. Untersuchungen mit inaktivierten Tollwut-Gewébekultue-Impfstoffen am tier
36. Canine distemper in pet dogs: I. Surveillance in Indiana during a suspected outbreak
37. Safety and efficacy of modified-live canine parvovirus vaccine
38. Canine infectious tracheobronchitis: Effects on an intranasal live canine parainfluenza-Bordetella bronchiseptica vaccine on viral shedding and clinical tracheobronchitis (kennel cough)
39. Outbreak of poliomyelitis in Finland in 1984
40. Résponse sérologique du chien après primovaccination antirabique a l'aide de vaccins adjuvés ou non
41. Influence of transplacentally acquired antibody on neonatal susceptibility to canine distemper virus in gnotobiotic dogs
42. Safety, efficacy and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine
43. Vaccination against canine bordetellosis using an aluminum hydroxide adjuvant vaccine
44. Serum distemper virus and parvovirus antibody titres among dogs brought to a veterinary hospital for revaccination
45. Vaccine protocol changes deemed premature. Canadian Veterinary Medical Association public statement of vaccine protocol
46. Pathogenesis of canine parvovirus enteritis. II. Sequential virus distribution and passive immunization
47. Efficacy of recombinant Lyme disease vaccination. International Forum on Ticks and Tickborne Disease
48. Duration of antibodies elicited by canine distemper virus vaccinations in dogs
49. Serum antibody response to canine parvovirus, canine adenovirus-1, and canine distemper virus in dogs with known status of immunization: Study of dogs in Sweden
50. The measles epidemic in Calgary, 1974-1975: The duration of protection conferred by vaccine
51. Canine distemper infection in pet dogs: II. A case-control study of risk factors during a suspected outbreak in Indiana
52. An appraisal of the value and method of use of living attenuated canine distemper vaccines
53. Maternally derived antibody to canine parvovirus: Transfer, decline and interference with immunization
54. Use of modified live feline panleukopenia virus vaccine to immunize dogs against canine parvovirus
55. The duration of immunity to an inactivated adjuvanted canine parvovirus vaccine
56. Modalité de production et immunité conferée par un vaccin antirabique inactive provenant de culture cellulaire
57. Persistence of antibodies following vaccination against canine distemper and the effect of revaccination
58. Comments on duration of vaccination immunity
59. Immune response to rabies vaccine in Alaskan dogs: Failure to achieve a consistently protective antibody response
60. Current and future canine and feline vaccination programs
61. Studies of a bacterin incorporating an extracted Bordetella bronchiseptica antigen for controlling canine bordetellosis
62. Rabies antibodies in vaccinated dogs
63. Rabies vaccines: Duration of immunity study in dogs
64. Vaccination against tetanus and diphtheria: Evaluation of immunity in the Danish population, guidelines for revaccination, and methods for control of vaccination programs
65. Current concepts - Are we vaccinating too much?
66. Protective levels of active immunity after vaccination with a MLV against CPV
67. Canine coronavirus infection in the dog following oronasal inoculation
68. Vaccination antirabique du chien: Réponse sérologique trois ans après un premier rappel a l'aide de vaccin contenant un adjuvant
69. An inactivated canine parvovirus vaccine: Duration of immunity and effectiveness in presence of maternal antibody